

Research and Reviews: Journal of Medical and Health Sciences

Momentum Trends in the Management of Gastroesophageal Reflux Disease: A Review

Chandana E^{1*}, Darion M²

¹Student, Sri Krishnadevaraya University, Anantapur, Andhra Pradesh, India

²Student, American University, USA

Research Article

Received: 02/08/2016

Accepted: 18/08/2016

Published: 23/08/2016

*For Correspondence

Chandana E, Student, Sri Krishnadevaraya University, Anantapur, Andhra Pradesh, India

E-Mail:

chandana.eddula@gmail.com

Keywords: Adenocarcinoma, Dysphagia, GERD, Esophagitis, Endoscopy.

ABSTRACT

Gastroesophageal reflux infection (GERD) is an interminable issue of the upper gastrointestinal tract with worldwide dispersion. The frequency is on the expansion in various parts of the world. In the last 30 to 40 years, researches discoveries have offered ascend to a more strong comprehension of its pathophysiology, clinical presentation, and administration. The suggestion is that the ailment can be unhesitatingly analyzed in view of manifestations alone. Nonerosive reflux disease (NERD) remains the overwhelming type of GERD. Non erosive reflux malady is an exceptionally heterogeneous gathering with huge cover with other utilitarian gastrointestinal issue. There is no best quality level for the analysis of GERD. Esophageal pH observing and intraluminal impedance checking have tossed some light on the heterogeneity of NERD. A considerable extent of GERD patients keep on having manifestations in spite of ideal PPI treatment, and this has required exploration into the improvement of new medications. A few security concerns have been raised about incessant utilization of proton pump inhibitors yet these are yet to be substantiated in controlled studies.

INTRODUCTION

Gastroesophageal reflux infection (GERD) is a typical perpetual issue pervasive in numerous nations. Aside from the financial weight of the ailment and its related effect on personal satisfaction, it is the most well-known inclining variable for adenocarcinoma of the throat [1-5]. As an outcome of the aggravation brought on by the reflux of corrosive and bile, adenocarcinoma may create in these patients, speaking to the remainder of a succession that begins with the improvement of GERD and advances to metaplasia (Barrett's throat), second rate dysplasia, high-review dysplasia, and adenocarcinoma [6-8]. In spite of the fact that there has been an abatement in the frequency of squamous cell diseases, the rate of esophageal adenocarcinoma has expanded quickly, and this has been followed to the coming of heftiness scourge, GERD and Barrett's throat [9-12].

DEFINITION

The absence of a highest quality level for analysis made it hard to embrace an agreeable definition. The primary ever worldwide agreement definition was distributed in 2006. As per that archive, GERD is characterized as "a condition which creates when the reflux of stomach substance causes troublesome manifestations and/or entanglements" [13-18]. This methodology is proper for most patients and does not utilize superfluous assets. Side effects achieve a limit where they constitute infection when they are troublesome to patients and influence their working amid regular exercises of living [19]. This patient-focused way to deal with conclusion incorporates asking patients how their side effects influence their regular lives.

Acid reflux and spewing forth are the trademark side effects of GERD. Acid reflux is characterized as a smoldering sensation in the retrosternal territory. Disgorging is characterized as the impression of stream of refluxed gastric substance into the mouth or hypopharynx [20-25]. These manifestations are adequately enlightening to be indicative. Esophageal and extraesophageal side effects and disorders that structure part of the system of

GERD additionally incorporate mid-section torment, rest unsettling influences, hack, roughness, asthma, and dental disintegrations [26-28].

EPIDEMIOLOGY

Gastroesophageal reflux disease is presently the most widely recognized upper gastrointestinal infection in the western nations, with 10% to 20% of the population encountering week after week indications [29-31]. Perceiving heart from non-cardiovascular midriff anguish is required before considering GERD as a purpose behind waist torment. In spite of the way that the symptom of dysphagia can be associated with uncomplicated GERD, its closeness warrants examination for a potential trouble including motility issue, stricture or threat. Endless hack, asthma, incessant laryngitis, other aviation route manifestations thus called extraesophageal indications are talked about in a resulting segment [32-39]. Atypical side effects including dyspepsia, epigastric agony, sickness, bloating, and burping might be characteristic of GERD however cover with different conditions. An orderly survey found that ~38% of the overall public whined of dyspepsia. Patients with troublesome GERD (day by day or >weekly side effects) had an expansion in time off work and decline in work profitability. Low scores on rest scales were seen contrasted and patients with less incessant manifestations. A decline in physical working was additionally seen. Nighttime GERD greaterly affects QOL contrasted and daytime side effects. Both nighttime manifestations and rest aggravations are basic to illustrate while assessing the GERD persistent. There is a distinct relationship amongst GERD and corpulence [40-45]. A few meta-examinations recommend a relationship between body mass index (BMI), midsection outline, weight pick up and the nearness of side effects and complexities of GERD including ERD and Barrett's throat.

RISK FACTORS

There is a potential hereditary part to the improvement of GERD and maybe Barrett's throat. In the US, in spite of the fact that the recurrence of GERD manifestations does not contrast amongst Caucasians and African Americans, the last gathering have a determinedly bring down danger of esophagitis [46-51]. There is confirmation to propose that age and male sex are connected with a higher occurrence of esophagitis. Stout subjects are 2.5 times more inclined to have GERD than those with ordinary body mass index (BMI). A few different scientists have reported comparable relationship between body mass and GERD [52-58]. Liquor utilization and the nearness of a break hernia are danger variables for GERD and esophagitis.

Gastroesophageal reflux disease is as often as possible found in patients with connective tissue sickness, particularly scleroderma, and in addition patients with interminable obstructive aviation route illness. What's more, various basic medications and hormonal items have been connected with GERD [59-61]. These incorporate anticholinergics, benzodiazepines, calcium channel blockers, dopamine, nicotine, nitrates, theophylline, estrogen, progesterone, glucagon, and a few prostaglandins. Acid reflux is an extremely basic gastrointestinal sign of pregnancy.

PATHOPHYSIOLOGY

Reflux is an ordinary physiologic event and is created frequently by transient unwinding of the lower esophageal sphincter (LES). In patients with GERD, these transient relaxations happen more habitually than typical. The basal weight of this sphincter is 10–45 mmHg. The crural stomach and gastric sling strands give auxiliary backing and add to LES weight and skill [62-65]. The capacity of the LES to keep up a tone higher than structures proximal and distal is a consequence of spikes of calcium convergence that are intervened by excitatory cholinergic neurons.

Under ordinary circumstances, endogenous barrier components either confine the measure of toxic material that is brought into the throat or quickly clear the material from the throat so that indications and esophageal mucosal disturbance are minimized [66-68]. Case of such protection components incorporates activities of the LES and typical esophageal motility. At the point when the guard instruments are damaged or get to be overpowered so that the throat is washed in corrosive or bile-containing liquid for delayed periods, GERD can be said to exist [69-81].

The throat, LES, and stomach can be compared to a basic pipes circuit. The throat capacities as an anterograde pump, the LES as a valve, and the stomach as a repository. The anomalies that add to GERD can come from any part of the framework [82-85]. A broken LES permits reflux of a lot of gastric juice. Postponed gastric discharging can expand volume and weight in the store until the valve component is overpowered, prompting GERD. Esophageal protection components incorporate esophageal leeway and mucosal resistance. Esophageal freedom has a mechanical arm (esophageal peristalsis) and a synthetic segment (spit), both of which utmost the measure of time the throat is presented to refluxed gastric juice [86-89].

As to impact of hiatal hernia, not all patients with hiatal hernias have symptomatic reflux. Within the sight of a hiatal hernia, the LES may relocate proximally into the mid-section and lose its stomach high-weight zone (HPZ), or the length of the HPZ may diminish ^[90-92]. The diaphragmatic rest might be extended by a substantial hernia, which hinders the capacity of the crura to work as an outer sphincter. Likewise the gastric substance might be caught in the hernia sac and reflux proximally into the throat amid unwinding of the LES. Diminishment of the hernias and crural conclusion result in the rebuilding of a satisfactory intra-stomach length of throat and reproducing the HPZ.

DIAGNOSIS

There is no best quality level for the finding of GERD. Endoscopy is sure in just around 40% of cases. Besides, the assessment of antireflux treatments depends on determination of side effects and this experiences significantly subjectivity ^[93]. The Society of American Gastrointestinal Endoscopic specialists (SAGES) Practice Guidelines stipulates that the determination of GERD can be affirmed if no less than one of the accompanying conditions exists: a mucosal break seen on endoscopy in a patient with run of the mill manifestations, Barrett's throat on biopsy, a peptic stricture without danger, or positive pH-metry ^[94]. This definition clearly avoids patients with NERD who are negative on pH-metry. Consequently, a target demonstrative instrument with satisfactory affectability and specificity remains an unmet requirement for clinicians and scientists.

Endoscopy

The endoscope has for quite some time been the essential instrument used to assess the esophageal mucosa in patients with manifestations suspected because of GERD. Discoveries of GERD incorporate erosive esophagitis, strictures, and a columnar lined throat eventually affirmed to be Barrett's throat ^[95]. All things considered, endoscopy has superb specificity for the finding of GERD particularly when erosive esophagitis is seen and the LA grouping is utilized. Be that as it may, by far most of patients with indigestion and spewing forth won't have disintegrations (or Barrett's) restricting upper endoscopy as an underlying demonstrative test in patients with suspected GERD ^[96]. Endoscopy considers biopsy of rings and strictures and screening for Barrett's. Albeit epidemiologic danger variables for Barrett's throat have been very much characterized (age more than 50, indications for >5–10 years, weight, male sex) the affectability and specificity of these side effects for anomalous endoscopy makes the utility of screening for Barrett's a dubious theme ^[97]. The expansion of esophageal biopsies as a subordinate to an endoscopic examination has been re-underlined as a result of the expanded predominance of eosinophilic esophagitis (EoE) ^[98]. Numerous clinicians routinely biopsy the throat in patients with reflux-sort side effects to search for EoE in the setting of an endoscopy that does not uncover erosive changes.

Esophageal manometry is of restricted quality in the essential finding of GERD. Neither a diminished lower esophageal sphincter weight, nor the nearness of a motility variation from the norm is sufficiently particular to make an analysis of GERD. Manometry ought to be utilized to help in arrangement of transnasal pH-impedance tests and is suggested before thought of antireflux surgery fundamentally to preclude achalasia or extreme hypomotility (scleroderma-like throat), conditions that would be contraindications to Nissen fundoplication, yet not to tailor the operation.

TREATMENT

The objectives of treatment incorporate help of side effects, recuperating of esophagitis, aversion of repeat, and anticipation of difficulties. The standards of treatment incorporate way of life changes and control of gastric corrosive discharge utilizing drugs or surgical treatment with restorative antireflux surgery.

Lifestyle/dietary modifications

These are viewed as the principal line of treatment. They incorporate weight reduction (for patients who are overweight); keeping away from liquor, chocolate, citrus juice, tomato-based items, peppermint, espresso, and onion. Different measures incorporate staying away from substantial suppers, diminishing fat admission, suspension of smoking, rise of leader of the bed, and maintaining a strategic distance from prostration for 3 hours postprandial. In spite of the fact that there are no randomized trials to test the viability of these measures, most gastroenterologists are of the conclusion that it is sensible to utilize them. Pregnant ladies who have GERD ought to be offered way of life alteration as first-line treatment.

Acid suppressive therapy

Right now, corrosive suppressive treatment frames the pillar of GERD treatment. Histamine 2 receptor adversaries (H2RAs) can diminish gastric corrosive emission after a dinner and are superior to anything acid neutralizers. They are not useful in the mending of esophagitis and support treatment with standard measurements of H2RAs can't forestall backslides ^[99]. Today they are utilized for the treatment of milder types of the illness and for on-interest treatment, particularly for nighttime manifestations.

Prokinetic operators are fairly successful however just in patients with mellow indications; different patients for the most part require extra corrosive stifling drugs, for example, PPIs. Metoclopramide is a regularly utilized individual from this gathering. Domperidone has the benefit of less extrapyramidal impacts ^[100]. Long haul utilization of prokinetic operators may have genuine, even possibly lethal inconveniences and ought to be disheartened. Randomized controlled trials give moderate-quality confirmation that prokinetic drugs enhance side effects in patients with reflux esophagitis and low-quality proof that they have sway on endoscopic recuperating.

Maintenance therapy

Repeat of esophagitis is generously decreased in patients who get day by day PPI treatment. Upkeep treatment for GERD is suggested at the most reduced powerful measurements. Proof from randomized controlled trials show that subjects regarded with a H2RA as support are twice as prone to have intermittent esophagitis as those treated with a PPI. In any case, among patients with NERD, on-interest regimens might be viable.

CONCLUSION

GERD is one a player in gastroenterology that has encountered massive progressions in the latest 30–40 years is still a scope of raised investigation. There have been progressions in the definition, portrayal, determination, clinical course, and organization of GERD. Nonerosive reflux sickness (NERD) is the variety of GERD that impacts more than 60% of patients with GERD and it is more heterogeneous than erosive esophagitis and has a substitute pathophysiology and response to standard restorative treatment. Since GERD is an unending, falling away from the faith infection, patients must be managed either whole deal restorative treatment or surgery after a watchful examination of the upsides and drawbacks of each procedure. Different issues stay questionable about GERD and it is assumed that the accompanying couple of years would go with more disclosures in this basic ailment.

REFERENCES

1. Testoni PA and Vailati C. Transoral incisionless fundoplication with EsophyX® for treatment of gastro-oesophageal reflux disease. *Diges Liver Dis.* 2012;44:631-635.
2. Perry KA et al. Radiofrequency energy delivery to the lower esophageal sphincter reduces esophageal acid exposure and improves GERD symptoms: a systematic review and meta-analysis. *Surg laparo endo percutan tech.* 2012;22:283–288.
3. Lipka, S et al. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. *Clin Gastroentero Hepat.* 2015;13:1058-1067.
4. Jafri SM et al. What is left of the endoscopic antireflux devices? *Curr Opin Gastroentero.* 2009;25:352-357.
5. Fedorak RN et al. Canadian Digestive Health Foundation Public Impact Series: Gastroesophageal reflux disease in Canada: Incidence, prevalence, and direct and indirect economic impact. *Canadian J Gastroentero.* 2010;24:431-434.
6. Heidelbaugh JJ et al. Overutilization of proton-pump inhibitors: What the clinician needs to know. *Therapeutic Advan Gastroentero.* 2012;5:219-232.
7. Forgacs I et al. Overprescribing proton pump inhibitors. *BMJ.* 2008;336:2-3.
8. Nardino RJ et al. Overuse of acid-suppressive therapy in hospitalized patients. *American J Gastroentero.* 2000;95:3118-3122.
9. Gupta R et al. Decreased acid suppression therapy overuse after education and medication reconciliation. *Int J Clin Pract.* 2013;67:60-65.
10. van der Pol RJ et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. *Pediatr.* 2011;127:925-935.
11. Tighe MP et al. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. *Paediatr Drugs.* 2009;11:185-202.
12. Mahadevan U and Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. *Gastroentero.* 2006;131:278-282.

13. Hopkins, J et al. Update on novel endoscopic therapies to treat gastroesophageal reflux disease: A review. *World J gastrointest endoscop.* 2015;7:1039-1044.
14. DeVault KR and Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. *Am J Gastroenterol.* 1999;94:1434-1442.
15. Hershcovici T and Fass R. Pharmacological management of GERD: where does it stand now?. *Trends pharmaco sci.* 2011;32:258-264.
16. Zajac P et al. An overview: Current clinical guidelines for the evaluation, diagnosis, treatment, and management of dyspepsia. *Osteopath Fam Phys.* 2013;5:79-85.
17. Kahrilas PJ. Gastroesophageal Reflux Disease. *New England J Med.* 2008;359:1700-1707.
18. Wang KK and Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. *Am J Gastroenterol.* 2008;103:788-797.
19. Piesman M et al. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter?. *Am J Gastroenterol.* 2007;102:2128-2134.
20. Ayazi S et al. Objective documentation of the link between gastroesophageal reflux disease and obesity. *Am J Gastroenterol.* 2007;102:138-139.
21. Ayazi S et al. Obesity and Gastroesophageal Reflux: Quantifying the Association Between Body Mass Index, Esophageal Acid Exposure, and Lower Esophageal Sphincter Status in a Large Series of Patients with Reflux Symptoms. *J Gastrointest Surg.* 2009;13:1440-1447.
22. Morse CA et al. Is there a relationship between obstructive sleep apnea and gastroesophageal reflux disease?. *Clin Gastroenterol Hepatol.* 2004;2:761-768.
23. Kasasbeh A et al. Potential mechanisms connecting asthma, esophageal reflux, and obesity/sleep apnea complex—a hypothetical review. *Sleep Med Rev.* 2007;11:47-58.
24. O'Connor HJ. Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. *Aliment Pharmacol Ther.* 1999;13:117-127.
25. El-Omar EM et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. *Gastroenterol.* 1997;113:15-24.
26. Fallone CA et al. There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with Helicobacter pylori". *Aliment Pharmacol Ther.* 2004; 20:761-768.
27. Kwok CS et al. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. *Int J Cardiol.* 2013 (in press).
28. Chen M et al. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. *Cardiovasc Ther.* 2012;30:e227-e233.
29. Havemann BD et al. The association between gastro-oesophageal reflux disease and asthma: a systematic review. *Gut.* 2007;56:1654-1664.
30. Irwin RS et al. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. *Am Rev Respir Dis.* 1990;141:640-647.
31. el-Serag HB and Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. *Gastroenterol.* 1997;113:755-760.
32. Ronkainen J et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. *Scand J Gastroenterol.* 2005;40:275-285.
33. Pandolfino JE and Vela MF. Esophageal-reflux monitoring. *Gastrointest Endosc.* 2009;69:917-930.
34. Smith J et al. New developments in reflux-associated cough. *Lung.* 2010;188:S81-S86.
35. Abou-Ismaïl A and Vaezi MF. Evaluation of patients with suspected laryngopharyngeal reflux: a practical approach. *Curr Gastroenterol Rep.* 2011;13:213-218.

36. Wiener GJ et al. The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. *Am J Gastroenterol.* 1988;83:358-361.
37. Weusten BL et al. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. *Gastroentero.* 1994;107:1741-1745.
38. Francis DO et al. Traditional reflux parameters and not impedance monitoring predict outcome after fundoplication in extraesophageal reflux. *Laryngoscop.* 2011;121:1902-1909.
39. Smith JA et al. Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. *Gastroentero.* 2010;139:754-762.
40. Vaezi MF et al. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. *Clin Gastroenterol Hepatol.* 2003;1:333-344.
41. Milstein CF et al. Prevalence of laryngeal irritation signs associated with reflux in asymptomatic volunteers: impact of endoscopic technique (rigid vs. flexible laryngoscope). *Laryngoscop.* 2005;115:2256-2261.
42. Branski RC et al. The reliability of the assessment of endoscopic laryngeal findings associated with laryngopharyngeal reflux disease. *Laryngoscop.* 2002;112:1019-1024.
43. Kiljander TO et al. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. *Am J Respir Crit Care Med.* 2010;181:1042-1048.
44. Harding SM and Sontag SJ. Asthma and gastroesophageal reflux. *Am J Gastroenterol.* 2000;95:S23-S32.
45. Chan WW et al. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis. *Arch Intern Med.* 2011;171:620-629.
46. Vakil N et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol.* 2006;101:1900-1920.
47. Moraes-Filho J et al. Brazilian consensus on gastroesophageal reflux disease: proposals for assessment, classification, and management. *Am J Gastroenterol.* 2002;97:241-248.
48. Diener U et al. Esophageal dysmotility and gastroesophageal reflux disease. *J Gastrointest Surg.* 2001;5:260-265.
49. Johnson LF and Demeester TR. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. *Am J Gastroenterol.* 1974;62:325-332.
50. Meneghetti AT et al. Esophageal mucosal damage may promote dysmotility and worsen esophageal acid exposure. *J Gastrointest Surg.* 2005;9:1313-1317.
51. Xu JY et al. Healing of severe reflux esophagitis with PPI does not improve esophageal dysmotility. *Dis Esophagus.* 2007;20:346-352.
52. CARRE IJ. Postural treatment of children with a partial thoracic stomach ('hiatus hernia'). *Arch Dis Child.* 1960;35:569-580.
53. Ott DJ et al. Association of hiatal hernia and gastroesophageal reflux: correlation between presence and size of hiatal hernia and 24-hour pH monitoring of the esophagus. *AJR Am J Roentgenol.* 1995;165:557-559.
54. Patti MG et al. Hiatal hernia size affects lower esophageal sphincter function, esophageal acid exposure, and the degree of mucosal injury. *Am J Surg.* 1996;171:182-186.
55. Gordon C et al. The role of the hiatus hernia in gastro-oesophageal reflux disease. *Aliment PharmacolTher.* 2004;20:719-732.
56. Sugiura T et al. Relationship between severity of reflux esophagitis according to the Los Angeles classification and esophageal motility. *J Gastroenterol.* 2001;36:226-230.
57. Semeniuk J et al. Manometric study of lower esophageal sphincter in children with primary acid gastroesophageal reflux and acid gastroesophageal reflux secondary to food allergy. *Adv Med Sci.* 2008;53:283-292.
58. Dodds WJ and Walter B. Cannon Lecture: current concepts of esophageal motor function: clinical implications for radiology. *AJR Am J Roentgenol.* 1977;128:549-561.

59. Mittal RK. Hiatal hernia: myth or reality? *Am J Med.* 1997;103:33S-39S.
60. Sloan S et al. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? *Ann Intern Med.* 1992;117:977-982.
61. van Herwaarden MA et al. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. *Gastroenterol.* 2000;119:1439-1446.
62. van Herwaarden MA et al. The role of hiatus hernia in gastro-oesophageal reflux disease. *Eur J Gastroenterol Hepatol.* 2004;16:831-835.
63. Gorenstein A et al. Hiatal hernia in pediatric gastroesophageal reflux. *J Pediatr Gastroenterol Nutr.* 2001;33:554-557.
64. Scarpato E et al. Impact of hiatal hernia on pediatric dyspeptic symptoms. *J Pediatr Gastroenterol Nutr.* 2014; 59:795-798.
65. Pensabene L et al. Mechanisms of gastroesophageal reflux in children with sequelae of birth asphyxia. *Brain Dev.* 2008;30:563-571.
66. Wu JF et al. Combined multichannel intraluminal impedance and pH monitoring assists the diagnosis of sliding hiatal hernia in children with gastroesophageal reflux disease. *J Gastroenterol.* 2013;48:1242-1248.
67. Berstad A et al. Relationship of hiatus hernia to reflux oesophagitis. A prospective study of coincidence, using endoscopy. *Scand J Gastroenterol.* 1986;21:55-58.
68. Kasapidis P et al. Effect of hiatal hernia on esophageal manometry and pH-metry in gastroesophageal reflux disease. *Dig Dis Sci.* 1995;40:2724-2730.
69. Jones MP et al. Impaired egress rather than increased access: an important independent predictor of erosive oesophagitis. *Neuro gastroenterol Motil.* 2002;14:625-631.
70. Mittal RK et al. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. *Gastroenterol.* 1987;92:130-135.
71. Sloan S and Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. *Gastroenterol.* 1991;100:596-605.
72. Dent J et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut.* 2005;54:710-717.
73. Hedley AA et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. *JAMA.* 2004;291:2847-2850.
74. Ogden CL et al. Prevalence of overweight and obesity in the United States, 1999-2004. *JAMA.* 2006;295:1549-1555.
75. Hampel H et al. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. *Ann Intern Med.* 2005;143:199-211.
76. El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. *Dig Dis Sci.* 2008;53:2307-2312.
77. Nilsson M et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. *JAMA.* 2003;290:66-72.
78. Zheng Z et al. Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. *Gastroenterol.* 2007;132:87-95.
79. Nocon M et al. Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study. *J Gastroenterol Hepatol.* 2007;22:1728-1731.
80. Jacobson BC et al. Body-mass index and symptoms of gastroesophageal reflux in women. *N Engl J Med.* 2006;354:2340-2348.
81. Ayazi S et al. Obesity and gastroesophageal reflux: quantifying the association between body mass index, esophageal acid exposure, and lower esophageal sphincter status in a large series of patients with reflux symptoms. *J Gastrointest Surg Offi J Soc Surg Alimen Tract.* 2009;13:1440-1447.

82. El-Serag HB et al. Obesity increases oesophageal acid exposure. *Gut*. 2007;56:749-755.
83. Crowell MD et al. Obesity is associated with increased 48-h esophageal acid exposure in patients with symptomatic gastroesophageal reflux. *Am J Gastroenterol*. 2009;104:553-559.
84. Pandolfino JE et al. Obesity: a challenge to esophagogastric junction integrity. *Gastroenterol*. 2006;130:639-649.
85. Blouin RA and Warren GW. Pharmacokinetic considerations in obesity. *J Pharm Sci*. 1999;88:1-7.
86. Jacobson BC. Body mass index and the efficacy of acid-mediating agents for GERD. *Dig Dis Sci*. 2008;53:2313-2317.
87. Barak N et al. Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. *Obes Rev*. 2002;3:9-15.
88. Cnop M et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. *Diabet*. 2002;51:1005-1015.
89. Tselepis C et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. *Oncogene*. 2002;21:6071-6081.
90. Ferrús JA et al. Management of gastroesophageal reflux disease in primary care settings in Spain. *Eur J Gastroenterol Hepatol*. 2009;21:1269-1278.
91. Martinucci I et al. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. *Neurogastroentero Motil: Offic J Euro Gastrointest Motil Soc*. 2014;26:546-55.
92. de Bortoli N et al. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? *Neurogastroenterol Motil*. 2014;26:28-35.
93. Lundell LR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. *Gut*. 1999;45:172-180.
94. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. *Am J Gastroenterol*. 1998;93:1028-1032.
95. El-Serag HB, et al. Anthropometric correlates of intragastric pressure. *Scand J Gastroenterol*. 2006;41:887-891.
96. Kim HJ et al. Influence of overweight and obesity on upper endoscopic findings. *J Gastroenterol Hepatol*. 2007;22:477-481.
97. Lee SW et al. Impact of body mass index and gender on quality of life in patients with gastroesophageal reflux disease. *World J Gastroenterol*. 2012;18:5090-5095.
98. Savarino E et al. Overweight is a risk factor for both erosive and non-erosive reflux disease. *Diges liver Dis: Offi J Italian Soc Gastroenterol Italian Asso Study Liver*. 2011;43:940-945.
99. Stene-Larsen G et al. Relationship of overweight to hiatus hernia and reflux oesophagitis. *Scand J Gastroenterol*. 1998;23:427-432.
100. Nilsson M et al. Body mass and reflux oesophagitis: an oestrogen-dependent association? *Scand J Gastroenterol*. 2002;37:626-630.